IP Library Granted Patent US 9,085,539
Granted Patent B2
US 9,085,539 · App. 13/831,929 · Granted Jul 21, 2015

Cyclic N,N′-diarylthiourea—androgen receptor antagonist, anti breast cancer composition and use thereof

Inventors: Alexandre Vasilievich Ivachtchenko (Encinitas, CA); Oleg Dmitrievich Mitkin (Moscow reg., RU)
C07D233/86C07D471/10C07D491/107
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,085,539
App. No.
13/831,929
Granted
Jul 21, 2015
Kind
B2
Abstract

The present invention relates to novel cyclic N,N′-diarylurea—androgen receptor antagonist, anti-cancer agent, pharmaceutical composition, medicament, and method for treatment of breast cancer disease. Cyclic N,N′-diarylthioureas or N,N′-diarylureas of the general formula 1, their optical (R)- and (S)-isomers and pharmaceutically acceptable salts thereof exhibiting properties of androgen receptor antagonists have been proposed, wherein: R1 represents C 1 -C 3 alkyl; R4 and R5 represent hydrogen; or R4 represents hydrogen, R5 represents methyl; or R4 represents methyl, R5 represents CH 2 R6 group in which R6 is C 1 -C 3 alkoxycarbonyl, carboxyl, hydroxyl group optionally substituted with methyl or benzyl; or R4 and R5 together with the carbon atom they are attached to form 5- or 6-membered saturated heterocycle including at least one oxygen atom or nitrogen atom optionally substituted with methyl.

Claims (7)

1. A pharmaceutical composition comprising a pharmaceutically effective amount of a 4-[3-(4-cyano-3-trifluoromethyl-phenyl)-4-oxo-2-thioxo-7-oxa-1,3-diaza-spiro[4.4]non-1-yl]-2-fluoro-benzimide compound of general formula 1 or an (R)-enantiomer thereof and a pharmaceutically acceptable carrier or an excipient

wherein:

R is C 1 -C 3 alkyl.

2. A pharmaceutical composition according to claim 1 , wherein the compound is 4-[(R)-3-(4-cyano-3-trifluoromethyl-phenyl)-4-oxo-2-thioxo-7-oxa-1,3-diaza-spiro[4.4]non-1-yl]-2-fluoro-benzimide represented by formula (R)-1

3. The composition according to claim 1 in the form of a capsule.

4. The composition according to claim 1 in the form of a tablet.

5. The composition according to claim 1 in the form of an injection.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2015
From: IVACHTCHENKO, ALEXANDRE VASILIEVICH
To: R-PHARM OVERSEAS INC.
Reel/Frame 037083/0514 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2015
From: MITKIN, OLEG DMITRIEVICH
To: IVACHTCHENKO, ALEXANDRE VASILIEVICH
Reel/Frame 035728/0822 →
Priority Claims (1)
RU 2010130618 · Jul 22, 2010 · national
Continuity (2)
Continuation In Part 13811282
Related Publication 20130252992A1 · Sep 26, 2013